Palvella Therapeutics, Inc. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
Palvella Therapeutics, Inc. (PVLA) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2024-11-13
- Palvella Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2024-06-30 was $0.00.
- Palvella Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2024-03-31 was $47.00K.
- Palvella Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2023-12-31 was $253.00K, a 84.67% increase year-over-year.
- Palvella Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $4.10M, a 846.65% increase from fiscal 2022.
- Palvella Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $433.00K, a 87.55% decline from fiscal 2021.
- Palvella Therapeutics, Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2021 was $3.48M.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $47.00K 10-Q · filed 2024-11-13 | $300.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $47.00K 10-Q · filed 2024-08-14 | $300.00K derived: sum of 3 quarters · filed 2024-08-14 | $4.25M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $47.00K 10-Q · filed 2024-05-15 | $300.00K derived: sum of 2 quarters · filed 2024-05-15 | $4.25M derived: sum of 3 quarters · filed 2024-11-13 | $4.22M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | $253.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $4.20M derived: sum of 2 quarters · filed 2024-11-13 | $4.17M derived: sum of 3 quarters · filed 2024-11-13 | $4.10M 10-K · filed 2024-03-29 |
| 2023-09-30 | $3.95M 10-Q · filed 2024-11-13 | $3.92M derived: sum of 2 quarters · filed 2024-11-13 | $3.85M 10-Q · filed 2024-11-13 | $3.98M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$31.00K 10-Q · filed 2024-08-14 | -$105.00K 10-Q · filed 2024-08-14 | $32.00K derived: sum of 3 quarters · filed 2024-08-14 | $290.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$74.00K 10-Q · filed 2024-05-15 | $63.00K derived: sum of 2 quarters · filed 2024-05-15 | $321.00K derived: sum of 3 quarters · filed 2024-05-15 | $551.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $395.00K derived: sum of 2 quarters · filed 2024-03-29 | $625.00K derived: sum of 3 quarters · filed 2024-03-29 | $433.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $258.00K 10-Q · filed 2023-11-14 | $488.00K derived: sum of 2 quarters · filed 2023-11-14 | $296.00K 10-Q · filed 2023-11-14 | $988.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $230.00K 10-Q · filed 2023-08-10 | $39.00K 10-Q · filed 2023-08-10 | $730.00K derived: sum of 3 quarters · filed 2023-08-10 | $2.00M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$192.00K 10-Q · filed 2023-05-11 | $500.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.77M derived: sum of 3 quarters · filed 2023-05-11 | $2.52M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.97M derived: sum of 2 quarters · filed 2023-03-31 | $2.71M derived: sum of 3 quarters · filed 2023-03-31 | $3.48M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.27M 10-Q · filed 2022-11-04 | $2.02M derived: sum of 2 quarters · filed 2022-11-04 | $2.79M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $745.00K 10-Q · filed 2022-08-04 | $1.51M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |